Special Drug Use Investigation of Xarelto [SPAF]
Latest Information Update: 26 Jul 2023
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Embolism; Myocardial infarction; Stroke
- Focus Adverse reactions; Therapeutic Use
- Acronyms XAPASS
- Sponsors Bayer
- 01 Sep 2020 Results (n=11,308 ) of sub-analysis of XAPASS assess long-term safety and effectiveness of reduced-dose rivaroxaban in high-risk NVAF patients for bleeding and thromboembolism presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology
- 03 Feb 2020 Status changed from active, no longer recruiting to completed.
- 08 Feb 2019 One year follow-up results (n=9578) were presented at the International Stroke Conference 2019.